Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2025-07-22 Earnings Release
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Strong Phase 2 data on iSCIB1+ in Melanoma
Earnings Release Classification · 100% confidence The document is an official announcement released via RNS (RNS Number : 9482R) on July 22, 2025, by Scancell Holdings Plc. It details strongly improved clinical outcomes from their Phase 2 SCOPE trial for an immunotherapy product (iSCIB1+). This content is a summary of clinical trial results, efficacy data, safety profiles, and future development plans (accelerating planning for a registrational Phase 2b/3 global study). This type of announcement, which reports specific operational/clinical progress and financial/scientific updates outside of mandatory periodic reports (like 10-K or IR), typically falls under a general regulatory announcement category. Since it is not a full Earnings Release (ER), a formal Interim Report (IR), a proxy statement (DEF 14A), or a specific transaction notice (DIV, POS, DIRS), the most appropriate classification is the general regulatory filing category, RNS, as it is explicitly distributed through the RNS system and contains material, non-periodic information. FY 2025
2025-07-22 English
Share Option Exercise
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (3826 characters) released via RNS (the news service of the London Stock Exchange) on July 16, 2025. The content details the exercise of share options by a former employee, the resulting increase in total voting rights, and the expected admission to trading of the new shares. This type of corporate action announcement, especially when disseminated through an official news service like RNS and concerning share capital changes (though not a formal SHA filing), fits best under the general regulatory announcement category, as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/director dealing report (DIRS). Given the nature of the announcement (share option exercise leading to a change in total voting rights) and its source (RNS), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory news releases that don't fit specific codes like DIV, SHA, or DIRS.
2025-07-16 English
Scancell initiates new arm in SCOPE Phase 2 study
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 2491O' and is dated '25 June 2025'. It details a clinical trial update (dosing commencement in Cohort 4 of the SCOPE Phase 2 study) and includes forward-looking statements and contact information typical of a corporate announcement. The presence of the RNS header and the nature of the content—a specific operational update rather than a full financial report (like 10-K or IR) or a proxy statement—strongly suggests it is a general regulatory announcement disseminated via the London Stock Exchange's RNS system. Since it is a specific operational/clinical update that doesn't fit perfectly into ER, CT, or CAP, the most appropriate general regulatory category is RNS, which serves as the fallback for miscellaneous regulatory filings.
2025-06-25 English
Director Dealing
Director's Dealing Classification · 100% confidence The document is a formal notification of a share purchase by a fund associated with a Non-Executive Director of Scancell Holdings plc. It explicitly uses the header 'Director Dealing' and follows the standard regulatory format for 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES' (PDMR). This aligns perfectly with the definition for Director's Dealing (DIRS).
2025-05-21 English
Partnership with NHS Cancer Vaccine Launch Pad
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service). It announces a new partnership between Scancell Holdings plc and the NHS Cancer Vaccine Launch Pad to fast-track clinical trial access. While it contains information about clinical trials, it is a corporate announcement of a business development/partnership event rather than a formal financial report, audit, or legal proceeding. As it does not fit into specific categories like M&A or Earnings Release, it falls under the general regulatory announcement category.
2025-04-14 English
Scancell to present at 2025 AACR Annual Meeting
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Scancell Holdings plc regarding the presentation of clinical trial data at an upcoming medical conference (AACR). It provides highlights of the trial results but is not a full financial report, nor is it a presentation deck itself. It functions as a news release announcing upcoming scientific disclosures. Given the RNS header and the nature of the content (announcing clinical trial results for investor awareness), it falls under the category of general regulatory announcements.
2025-04-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.